Background：Ifabotuzumab formerly KB004 is a first-in-class therapeutic non-fucosylated IgG1 human f-allotype monoclonal antibody being developed by Humanigen formerly KaloBios Pharmaceuticals for the treatment of cancer. The drug was licensed from the Ludwig Institute for Cancer Research. The molecule contains a human antibody constant region with V-regions that are 92% identical to human germ-line sequences. Ifabotuzumab targets the ephrin type-A receptor 3 EphA3 tyrosine kinase. In non-clinical studies, Ifabotuzumab demonstrated potent ex-vivo cell killing of EphA3+ tumor cells obtained from patients with hematologic malignancies.
